Genelux (GNLX) Retained Earnings (2022 - 2026)

Genelux (GNLX) posted quarterly Retained Earnings of -$5000.0 for Q1 2026, down 155.56% quarter-over-quarter from $9000.0 in Q4 2025.

Genelux (GNLX) Retained Earnings (2022 - 2026) Analysis & Trends

Genelux's Retained Earnings history runs 5 years deep, the most recent figure standing at -$5000.0 for Q1 2026.

In Q1 2026, Retained Earnings changed N/A year-over-year to -$5000.0; the TTM figure through Mar 2026 stood at -$5000.0 (changed N/A YoY), while the FY2025 annual figure was $9000.0, up 100.0% from the prior year.
Retained Earnings for Q1 2026 stood at -$5000.0, down from $9000.0 in the prior quarter.
The five-year high for Retained Earnings was $290.6 million in Q2 2025, with the low at -$251.4 million in Q4 2024.
The 5-year median for Retained Earnings is $154.4 million (2022), against an average of $111.8 million.
Peak annual rise in Retained Earnings reached 13789000.0% in 2024, while the deepest fall reached 204.14% in 2024.
Genelux's Retained Earnings stood at $154.4 million in 2022, then soared by 56.34% to $241.4 million in 2023, then plunged by 204.14% to -$251.4 million in 2024, then soared by 100.0% to $9000.0 in 2025, then sank by 155.56% to -$5000.0 in 2026.
Business Quant data shows GNLX's Retained Earnings at -$5000.0 in Q1 2026, $9000.0 in Q4 2025, and $8000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Retained Earnings (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	15.69 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	37.62 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	558.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	5.10 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	13.05 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-6.33 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	20.91 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.57 Bn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	4.38 Bn
10	Genelux	119.87 Mn	119.87 Mn	-	315.78 Mn

Download Data